AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER).

How it works

Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy. Dextrose stimulates insulin release, promoting cellular uptake of amino acids.

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and urea cycle in the liver; dextrose undergoes glycolysis and oxidative phosphorylation.
Excretion	Amino acids are primarily metabolized; nitrogen is excreted as urea (renal, ~85%) and ammonia (renal, ~2-5%); glucose is fully metabolized to CO2 and water (exhaled and renal); electrolytes are excreted renally. Less than 5% excreted unchanged renally.
Half-life	Not applicable as a single entity; amino acids have rapid plasma clearance (t1/2 of minutes to hours) and dextrose is rapidly cleared (t1/2 ~1-2 hours). Clinical context: Continuous infusion maintains steady state.
Protein binding	Amino acids: variable (e.g., tryptophan ~90% bound to albumin; others <20%). Dextrose: negligible (<5%). Overall minimal.
Volume of Distribution	Amino acids distribute into total body water (~0.6 L/kg); dextrose distributes into extracellular fluid (~0.2 L/kg). Overall Vd ~0.4-0.6 L/kg.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: Immediate upon infusion; restoration of amino acid levels and glucose utilization begins within minutes.
Duration of Action	Duration is dependent on infusion rate and metabolic demand. Clinical note: Must be continuously infused; effects last only as long as infusion continues.

Classification & Brands

Dosing & administration

Intravenous administration based on protein requirements: 1.0-2.0 g/kg/day amino acids, corresponding to 20-40 mL/kg/day of AMINOSYN II 5% in DEXTROSE 25%. Typical adult dose starts at 30-40 mL/hour, titrated to metabolic goals.

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: reduce to 0.8-1.2 g/kg/day amino acids. GFR 15-29 mL/min: 0.6-0.8 g/kg/day. GFR <15 mL/min: 0.6 g/kg/day or avoid if not on dialysis.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce to 0.8-1.2 g/kg/day amino acids. Child-Pugh C: 0.6-0.8 g/kg/day, consider branched-chain amino acid formulations.
Pediatric use	Neonates: 2.0-3.5 g/kg/day amino acids (40-70 mL/kg/day). Infants: 1.5-3.0 g/kg/day (30-60 mL/kg/day). Children: 1.0-2.0 g/kg/day (20-40 mL/kg/day). Administer intravenous.
Geriatric use	No specific dose adjustment; monitor renal function and fluid status. Start at lower end of adult range (1.0-1.5 g/kg/day amino acids) and titrate based on tolerance and metabolic response.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER).

Breastfeeding

No data on excretion of Aminosyn II 5% or dextrose 25% in human milk. Dextrose is a normal component of breast milk; amino acids are present endogenously. Intravenous administration may alter maternal plasma concentrations, but transfer to milk is likely negligible. M/P ratio is unknown. Consider benefits of breastfeeding and potential risks to infant; monitor infant for any adverse effects such as gastrointestinal disturbances.

Teratogenic Risk

Aminosyn II 5% in Dextrose 25% is a combination of amino acids and dextrose used for parenteral nutrition. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted with this combination. Dextrose at high doses may cause fetal hyperinsulinism and hypoglycemia. Use only if clearly needed, weighing potential benefits against unknown fetal risks. First trimester: Theoretical risk of metabolic disturbances; second and third trimesters: Risk of maternal hyperglycemia leading to fetal macrosomia, neonatal hypoglycemia, and other complications if blood glucose not controlled.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Inborn errors of amino acid metabolism (e.g., maple syrup urine disease, phenylketonuria)","Severe hyperglycemia or diabetic coma","Severe electrolyte disturbances","Patients with anuria or oliguria due to renal failure","Hypersensitivity to any component"]

Clinical Precautions

Precautions	["Risk of hyperglycemia, especially in diabetic or stressed patients; monitor blood glucose","Electrolyte imbalances, particularly hyperkalemia, hypophosphatemia, or hypomagnesemia","Fluid overload in patients with renal or cardiac impairment","Refeeding syndrome in severely malnourished patients","Monitor liver function tests due to potential hepatotoxicity from amino acids"]
Food/Dietary	Do not administer with foods or oral feeds; compatible with standard parenteral nutrition additives; avoid concurrent use with medications that cause hyperglycemia unless monitored.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

Clinical safety rating: caution

Comprehensive clinical and safety monograph for AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER).

How it works

Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy. Dextrose stimulates insulin release, promoting cellular uptake of amino acids.

What the body does with it

Metabolism	Amino acids are metabolized via transamination, deamination, and urea cycle in the liver; dextrose undergoes glycolysis and oxidative phosphorylation.
Excretion	Amino acids are primarily metabolized; nitrogen is excreted as urea (renal, ~85%) and ammonia (renal, ~2-5%); glucose is fully metabolized to CO2 and water (exhaled and renal); electrolytes are excreted renally. Less than 5% excreted unchanged renally.
Half-life	Not applicable as a single entity; amino acids have rapid plasma clearance (t1/2 of minutes to hours) and dextrose is rapidly cleared (t1/2 ~1-2 hours). Clinical context: Continuous infusion maintains steady state.
Protein binding	Amino acids: variable (e.g., tryptophan ~90% bound to albumin; others <20%). Dextrose: negligible (<5%). Overall minimal.
Volume of Distribution	Amino acids distribute into total body water (~0.6 L/kg); dextrose distributes into extracellular fluid (~0.2 L/kg). Overall Vd ~0.4-0.6 L/kg.
Bioavailability	Intravenous: 100%.
Onset of Action	Intravenous: Immediate upon infusion; restoration of amino acid levels and glucose utilization begins within minutes.
Duration of Action	Duration is dependent on infusion rate and metabolic demand. Clinical note: Must be continuously infused; effects last only as long as infusion continues.

Classification & Brands

Dosing & administration

Dosage form	INJECTABLE
Renal impairment	GFR 30-59 mL/min: reduce to 0.8-1.2 g/kg/day amino acids. GFR 15-29 mL/min: 0.6-0.8 g/kg/day. GFR <15 mL/min: 0.6 g/kg/day or avoid if not on dialysis.
Liver impairment	Child-Pugh A: no adjustment. Child-Pugh B: reduce to 0.8-1.2 g/kg/day amino acids. Child-Pugh C: 0.6-0.8 g/kg/day, consider branched-chain amino acid formulations.
Pediatric use	Neonates: 2.0-3.5 g/kg/day amino acids (40-70 mL/kg/day). Infants: 1.5-3.0 g/kg/day (30-60 mL/kg/day). Children: 1.0-2.0 g/kg/day (20-40 mL/kg/day). Administer intravenous.
Geriatric use	No specific dose adjustment; monitor renal function and fluid status. Start at lower end of adult range (1.0-1.5 g/kg/day amino acids) and titrate based on tolerance and metabolic response.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER (AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER).

Breastfeeding

Teratogenic Risk

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

Clinical Precautions

Precautions	["Risk of hyperglycemia, especially in diabetic or stressed patients; monitor blood glucose","Electrolyte imbalances, particularly hyperkalemia, hypophosphatemia, or hypomagnesemia","Fluid overload in patients with renal or cardiac impairment","Refeeding syndrome in severely malnourished patients","Monitor liver function tests due to potential hepatotoxicity from amino acids"]
Food/Dietary	Do not administer with foods or oral feeds; compatible with standard parenteral nutrition additives; avoid concurrent use with medications that cause hyperglycemia unless monitored.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

Clinical Pearls	Aminosyn II 5% in Dextrose 25% is a high-calorie parenteral nutrition solution; monitor serum glucose closely due to high dextrose load; requires central line administration due to osmolarity >900 mOsm/L; assess for refeeding syndrome in malnourished patients; check electrolytes including phosphate, magnesium, and potassium before initiation.
Patient Advice	This solution is given through a central vein to provide nutrition when you cannot eat. · Report any signs of infection at the IV site, such as redness, swelling, or pain. · You may need frequent blood tests to monitor your blood sugar and electrolyte levels. · Tell your doctor if you experience symptoms of high blood sugar, such as increased thirst, urination, or confusion.